ArticleNPJ precision oncology2025
Breast cancer homologous recombination deficiency prediction from pathological images with a sufficient and representative Transformer.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating Multimodal MRI Habitat and Transformer-Based Pathomics to Predict High-Risk Molecular Subtypes and Explore Biological Mechanisms in Adult Diffuse Gliomas.CNS neuroscience & therapeutics · 2026Article
- Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective.Biomarker research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Homologous recombination deficiency (HRD) has been recognized as a key biomarker for poly-ADP ribose polymerase inhibitors (PARPi) and platinum-based chemotherapy in breast cancer (BC). HRD prediction typically relies on molecular biology assays, which have a high turnaround time, and cost. In contrast, tissue sections stained with hematoxylin and eosin (H&E) are ubiquitously available. However, current HRD prediction methods that utilize pathological images are usually based on attention-based multiple instance learning, which is ineffective for modeling the global context of whole slide images (WSIs). To address this challenge, we propose a Sufficient and Representative Transformer (SuRe-Transformer) for WSI-based prediction of HRD. Experimental results demonstrate the superior performance of SuRe-Transformer in predicting HRD status compared to state-of-the-art methods, achieving an AUROC of 0.887 ± 0.034. Furthermore, SuRe-Transformer demonstrates generalizability across multiple external patient cohorts and achieves state-of-the-art performance in predicting several gene mutation biomarkers from BC WSIs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.